Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001753551 | SCV002007266 | uncertain significance | not provided | 2021-09-02 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant does not alter protein structure/function; Located in exon 38, which is reported as being expressed in a brain-specific transcript (Otto et al, 1991; Cunha et al, 2008; Wu et al, 2015) |
Ambry Genetics | RCV004019892 | SCV005016703 | uncertain significance | Cardiovascular phenotype | 2023-12-21 | criteria provided, single submitter | clinical testing | The p.S2195N variant (also known as c.6584G>A), located in coding exon 38 of the ANK2 gene, results from a G to A substitution at nucleotide position 6584. The serine at codon 2195 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Blueprint Genetics | RCV000157110 | SCV000206833 | uncertain significance | Long QT syndrome | 2014-07-07 | no assertion criteria provided | clinical testing |